The relationship between myocardial viability and plasma NT-proBNP levels

Öz

Aim: There is no biochemical marker that indicates myocardial viability in the late phase after myocardial infarction. The aim of our study was to identify whether plasma NT-proBNP levels indicate the presence of viable myocardium after myocardial infarction.

Material and Methods: Patients with myocardial infarction and left ventricular ejection fraction of less than 45% were included in the study. Exercise or pharmacological myocardial perfusion scintigraphy was performed to investigate viability in the infarction region. The left ventricle was divided into 19 segments where the necrotic area and viable myocardium within it was measured. Blood samples for NT-proBNP measurement were obtained from all patients on the same day scintigraphy performed.

Results: A total of 60 patients were included in the study (10 females, 50 males, mean age 62 ± 9 years). 48 (80%) patients underwent exercise scintigraphy. The mean exercise time was 7.1 ± 2.3 minutes. The infarct area was located in anterior segments in 16 patients, inferior in 25, and in both locations in 19 patients. The mean left ventricular ejection fraction was 36 ± 8%. There was a negative correlation between left ventricular ejection fraction and serum NT-proBNP levels (r = -0.03 p <0.01). On the other hand, there was no correlation between plasma NT-proBNP levels and the presence or extent of viable myocardium within the necrotic area (P = 0.8).

Conclusion: There was no correlation between plasma NT-proBNP levels and the presence of viable myocardium in the infarct zone in patients with myocardial infarction

Anahtar Kelimeler

• myocardial infarction,viable myocardium,NT-proBNP

Kaynakça

1. References
2. 1. Perelshtein Brezinov O, Klempfner R, Zekry S Ben, Goldenberg I, et al. Prognostic value of ejection fraction in patients admitted with acute coronary syndrome: A real world study. Medicine (Baltimore). 2017; 96: e6226. 2. Singh P, Sethi N, Kaur N, Kozman H. Revascularization in Severe Left Ventricular Dysfunction: Does Myocardial Viability Even Matter? Clin Med Insights Cardiol. 2015; 9: 105-109. 3. Yao S-S, Chaudhry FA. Assessment of myocardial viability with dobutamine stress echocardiography in patients with ischemic left ventricular dysfunction. Echocardiography. 2005; 22: 71-83. 4. Underwood SR, Bax JJ, vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J. 2004; 25: 815-836. 5. Ibrahim N, Januzzi JL. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev Cardiovasc Ther. 2015; 13: 1017-1030. 6. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004; 6: 261-268. 7. Volpe M, Battistoni A, Rubattu S. Natriuretic peptides in heart failure: Current achievements and future perspectives. Int J Cardiol. 2019; 281: 186-189. 8. Brunner-La Rocca H-P, Eurlings L, Richards AM, et al. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail. 2015; 17: 1252-1261.
3. 9. Palazzuoli A, Ruocco G, Cekorja B, Pellegrini M, et al . Combined BNP and Echocardiographic assessment in interstitial lung disease for pulmonary hypertension detection. Int J Cardiol. 2015; 178: 34-36. 10. Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol. 1999; 10: 2426-2439. 11. Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J Off Publ Fed Am Soc Exp Biol. 2003; 17: 1105-1107. 12. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004; 44: 335-339. 13. Weber M, Dill T, Arnold R, et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J. 2004; 148: 612-620. 14. Oremus M, Raina PS, Santaguida P, et al. A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. Clin Biochem. 2008; 41: 260-265. 15. Sarullo FM, Gristina T, Brusca I, et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels in predicting residual myocardial ischemia in patients with ST elevation acute myocardial infarction. Minerva Cardioangiol. 2007; 55: 149-155. 16. Zaid G, Tanchilevitch A, Rivlin E, et al. Diagnostic accuracy of serum B-type natriuretic peptide for myocardial ischemia detection during exercise testing with spect perfusion imaging. Int J Cardiol. 2007; 117: 157-164. doi:10.1016/j.ijcard.2006.06.013